Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder

References

• The National Institute of Mental Health. Major depression. mental health information - statistics. [ Published February 2019]. Available from: https://www.nimh.nih.gov/health/statistics/major-depression.shtml#part_155029. Accessed September 18, 2018..
   Google Scholar
• Bose J, Hedden SL, Lipari RN, Park-Lee E. Key Substance Use and Mental Health Indicators in the United States: Results from the 2017 National Survey on Drug Use and Health. Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2018. Available from: https://www.samhsa.gov/data/. Accessed December 12, 2019.
   Google Scholar
• Chow W, Doane MJ, Sheehan J, Alphs L, Le H. Economic burden among patients with major depressive disorder: an analysis of healthcare resource use, work productivity, and direct and indirect costs by depression severity. Am J Manag Care. 2019;16:e188–e196.
   Google Scholar
• Greenberg PE, Fournier -A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–162. doi:10.4088/JCP.14m09298
   PubMed Web of Science ®Google Scholar
• Patkar AA, Pae C-U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27(S1):29–37. doi:10.1007/s40263-012-0031-0
   Web of Science ®Google Scholar
• Wen XJ, Wang LM, Liu ZL, Huang A, Liu YY, Hu JY. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Braz J Med Biol Res. 2014;47(7):605–616. doi:10.1590/1414-431X20143672
   Web of Science ®Google Scholar
• Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract. 2008;14(1):34–44. doi:10.1097/01.pra.0000308493.93003.92
   Web of Science ®Google Scholar
• McIntyre RS, Weiller E. Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study. Adv Ther. 2015;32(5):429–444. doi:10.1007/s12325-015-0207-3
   PubMed Web of Science ®Google Scholar
• Nadkarni A, Kalsekar Y, Hebden F. Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy. Clin Outcomes Res. 2013;5:49–57. doi:10.2147/CEOR.S36526
   PubMedGoogle Scholar
• Eaves S, Rey JA. Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder. P T Peer-Rev J Formul Manag. 2016;41(7):418–422.
   Google Scholar
• Al Shirawi MI, Edgar NE, Kennedy SH. Brexpiprazole in the treatment of major depressive disorder. Clin Med Insights Ther. 2017;9:1179559X1773180. doi:10.1177/1179559X17731801
   Google Scholar
• Fava M, Okame T, Matsushima Y, Perry P, Weiller E, Baker RA. Switching from inadequate adjunctive or combination treatment options to brexpiprazole adjunctive to antidepressant: an open-label study on the effects on depressive symptoms and cognitive and physical functioning. Int J Neuropsychopharmacol. 2016;20(1):22–30. doi:10.1093/ijnp/pyw087
   Web of Science ®Google Scholar
• Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I. Medication adherence, health care utilization, and costs in patients with major depressive disorder initiating adjunctive atypical antipsychotic treatment. Clin Ther. 2019;41:221–232. doi:10.1016/j.clinthera.2018.12.005
   PubMed Web of Science ®Google Scholar
• Gauthier G, Guérin A, Zhdanava M, et al. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. BMC Psychiatry. 2017;17(1):222. doi:10.1186/s12888-017-1385-0
   PubMed Web of Science ®Google Scholar
• Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016;173(4):400–407. doi:10.1176/appi.ajp.2015.15060770
   PubMed Web of Science ®Google Scholar
• Fava M, Durgam S, Earley W, et al. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018;33(6):312–321. doi:10.1097/YIC.0000000000000235
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(03):371–378. doi:10.4088/JCP.15m10070
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. doi:10.1016/0895-4356(92)90133-8
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. HCUP chronic condition indicator. healthcare cost and utilization project (HCUP). [ Published June 2015]. Available from: www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp. Accessed January 18, 2020.
   Google Scholar
• Nau D. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. Springfield (VA): Pharmacy Quality Alliance; 2012. Available from: http://www.pqaaliance.org/files/PDCvsMPRfinal.pdf. Accessed August 29, 2016.
   Google Scholar
• Deb P, Norton EC. Modeling health care expenditures and use. Annu Rev Public Health. 2018;39(1):489–505. doi:10.1146/annurev-publhealth-040617-013517
   Web of Science ®Google Scholar
• Waite R. Use of second generation antipsychotics for treatment-resistant major depressive disorder. Ment Health Clin. 2014;4(5):246–256. doi:10.9740/mhc.n207192
   Google Scholar
• Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. Hay PJ, ed. PLoS Med. 2013;10(3):e1001403. doi:10.1371/journal.pmed.1001403
   PubMed Web of Science ®Google Scholar
• Halpern R, Nadkarni A, Kalsekar I, et al. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data. Ann Pharmacother. 2013;47(7–8):933–945. doi:10.1345/aph.1R622
   Web of Science ®Google Scholar
• Sussman M, Yu J, Kamat SA, et al. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. J Affect Disord. 2017;207:54–62. doi:10.1016/j.jad.2016.09.006
   PubMed Web of Science ®Google Scholar
• Seetasith A, Greene M, Hartry A, Burudpakdee C. Real-world economic outcomes of brexpiprazole and extended-release quetiapine adjunctive use in major depressive disorder. Clin Outcomes Res. 2019;11:741–755. doi:10.2147/CEOR.S220007
   PubMed Web of Science ®Google Scholar
• Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S. Second-generation antipsychotics for major depressive disorder and dysthymia. In: The Cochrane Collaboration editor, Cochrane Database of Systematic Reviews. Chichester (UK): John Wiley & Sons, Ltd; 2010. doi:10.1002/14651858.CD008121.pub2
   Google Scholar
• Seetasith A, Greene M, Hartry A, Burudpakdee C. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder. J Med Econ. 2018;21(9):888–901. doi:10.1080/13696998.2018.1484373
   PubMed Web of Science ®Google Scholar
• Halfin A. Depression: the benefits of early and appropriate treatment. Am J Manag Care. 2007;13:S92–S97.
   PubMed Web of Science ®Google Scholar
• Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment. J Am Coll Cardiol. 2017;69(3):345–357. doi:10.1016/j.jacc.2016.10.060
   PubMed Web of Science ®Google Scholar
• Lopez MJ, Gutman R. Estimation of causal effects with multiple treatments: a review and new ideas. Stat Sci. 2017;32(3):432–454. doi:10.1214/17-STS612
   Web of Science ®Google Scholar